Retatrutide, a experimental dual agonist of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) binding site , is exhibiting promising results in preliminary patient assessments . Ongoing https://explorebookmarks.com/story21268572/retatrutide-emerging-studies-and-projected-clinical-roles